Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205458 | 0.86 | KMT2A (0.43) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL3952959 | 0.84 | NR3C1 (0.46) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL24119464 | 0.83 | NR3C1 (0.43) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL21448622 | 0.82 | NR3C1 (0.46) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL12230864 | 0.80 | NR3C1 (0.41) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL3353198 | 0.80 | NR3C1 (0.41) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL5060606 | 0.77 | MAOA (0.52) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL12230856 | 0.77 | NR3C1 (0.43) | NR3C1 | |
| SCHEMBL12205540 | 0.77 | NR3C1 (0.63) | MAOAMAOBNR3C1ATMPKM | |
| SCHEMBL12142430 | 0.77 | HTR2A (0.43) | MAOAMAOBNR3C1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112334457-A | Process for preparing tricyclic compounds | 拜耳公司 | 2021-02-05 | — | — | CN | claimed |
| CN-112334457-A | Process for preparing tricyclic compounds | 拜耳公司 | 2021-02-05 | — | — | CN | disclosed |
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | disclosed |
| US-8492407-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8450362-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8017617-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2178891-A2 | PHOSPHONOUS ACIDS, SALTS AND ESTERS, METHODS FOR THE PRODUCTION THEREOF, AND USE OF SAME | Clariant Finance (BVI) Limited (VG) | 2010-04-28 | — | — | EP | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009010188-A2 | ALKYLPHOSPHONOUS ACIDS, SALTS AND ESTERS, METHODS FOR THE PRODUCTION THEREOF, AND USE OF SAME | CLARIANT INTERNATIONAL LTD (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | MAOA 597/4885MAOB 594/4885NR3C1 509/4885 |
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | MAOA 1728/4885MAOB 2148/4885NR3C1 1033/4885 |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | MAOA 597/4885MAOB 594/4885NR3C1 509/4885 |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | CHRM2, CHRM5, CHRM3 | MAOA 914/4885MAOB 1312/4885NR3C1 293/4885 |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | MAOA 615/4885MAOB 366/4885NR3C1 747/4885 |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM1 | MAOA 597/4885MAOB 594/4885NR3C1 509/4885 |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | MAOA 1728/4885MAOB 2148/4885NR3C1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.